Sentence comprehension involves a host of highly interrelated processes, including syntactic parsing, semantic composition, and pragmatic inferencing. In neuroimaging, a primary paradigm for examining the brain bases of sentence processing has been to compare brain activity elicited by sentences versus unstructured lists of words. These studies commonly find an effect of increased activity for sentences in the anterior temporal lobes (aTL). Together with neuropsychological data, these findings have motivated the hypothesis that the aTL is engaged in sentence level combinatorics. Combinatoric processing during language comprehension, however, occurs within tens and hundreds of milliseconds, i.e., at a time-scale much faster than the temporal resolution of hemodynamic measures. Here, we examined the time-course of sentence-level processing using magnetoencephalography (MEG) to better understand the temporal profile of activation in this common paradigm and to test a key prediction of the combinatoric hypothesis: because sentences are interpreted incrementally, word-by-word, activity associated with basic linguistic combinatorics should be time-locked to word-presentation. Our results reveal increased anterior temporal activity for sentences compared to word lists beginning approximately 250 ms after word onset. We also observed increased activation in a network of other brain areas, extending across posterior temporal, inferior frontal, and ventral medial areas. These findings confirm a key prediction of the combinatoric hypothesis for the aTL and further elucidate the spatio-temporal characteristics of sentence-level computations in the brain.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuroimage.2012.01.030DOI Listing

Publication Analysis

Top Keywords

brain activity
8
activity associated
8
sentence processing
8
activity sentences
8
anterior temporal
8
hypothesis atl
8
key prediction
8
prediction combinatoric
8
combinatoric hypothesis
8
brain
5

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

ECU, Perth, Western Australia, Australia.

Background: The autophagy lysosomal pathway (ALP) and the ubiquitin-proteasome system (UPS) are key proteostasis mechanisms in cells, which are dysfunctional in AD and linked to protein aggregation and neuronal death. Autophagy is over activated in Alzheimer's disease brain whereas UPS is severely impaired. Activating autophagy has received most attention, however recent evidence suggests that UPS can clear aggregate proteins and a potential therapeutic target for AD and protein misfolding diseases.

View Article and Find Full Text PDF

Background: Pycnanthus angolensis (Welw) Warb., Myristicaceae, is used extensively in ethnomedicine. Numerous health benefits have being ascribed to the use of different parts of P.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Suven Life Sciences, Hyderabad, Telangana, India.

Background: Alzheimer's disease (AD) agitation is a distressing neuropsychiatric symptom characterized by excessive motor activity, verbal aggression, or physical aggression. Agitation is one of the causes of caregiver distress, increased morbidity and mortality, and early institutionalization in patients with AD. Current medications used for the management of agitation have modest efficacy and have substantial side effects.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Aptah Bio Inc., San Carlos, CA, USA.

Background: Alzheimer's disease (AD) is the most common cause of dementia worldwide. It is characterized by dysfunction in the U1 small nuclear ribonucleoproteins (snRNPs) complex, which may precede TAU aggregation, enhancing premature polyadenylation, spliceosome dysfunction, and causing cell cycle reentry and death. Thus, we evaluated the effects of a synthetic single-stranded cDNA, called APT20TTMG, in induced pluripotent stem cells (iPSC) derived neurons from healthy and AD donors and in the Senescence Accelerated Mouse-Prone 8 (SAMP8) model.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Cognition Therapeutics, Purchase, NY, USA.

Background: CT1812 is an experimental therapeutic sigma-2 receptor modulator in development for Alzheimer's disease (AD) and dementia with Lewy bodies. CT1812 reduces the affinity of Aβ oligomers to bind to neurons and exert synaptotoxic effects. This phase 2, multi-center, international, randomized, double-blind, placebo-controlled trial assessed safety, tolerability and effects of CT1812 on cognitive function in individuals with AD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!